Hospital Authority

This intelligence profile covers a Phase 2 clinical trial (IIT2016007) sponsored by Hospital Authority, Hong Kong, investigating cytarabine in acute myeloid leukemia (AML). The trial, registered as NCT03031262, represents an investigator-initiated study combining cytarabine, a DNA polymerase inhibitor approved globally for hematologic malignancies, with chidamide, a histone deacetylase inhibitor under clinical investigation in China. Cytarabine is a well-established antineoplastic agent with decades of clinical use; the combination approach aims to explore potential synergistic effects in AML treatment. The program remains active as of May 2025, with the latest milestone recorded on 30 May 2025. Cytarabine maintains approved status in multiple jurisdictions including the United States (via multiple generic manufacturers), Australia (Pfizer), and China (clinical trials ongoing). The trial design and specific endpoints have not been disclosed. No commercial partnership or licensing arrangement is documented for this investigator-initiated study.

Acute myeloid leukemia remains a serious hematologic malignancy with significant unmet medical needs, particularly in elderly patients and those with relapsed or refractory disease. Cytarabine has been a cornerstone of AML therapy for decades, but resistance and toxicity remain clinical challenges. The combination of cytarabine with chidamide, a histone deacetylase inhibitor, represents a rational approach to potentially enhance therapeutic efficacy through dual mechanisms targeting DNA synthesis and epigenetic regulation. This investigator-initiated trial, conducted by a major healthcare authority in Hong Kong, provides clinical evidence generation outside traditional pharmaceutical sponsorship models, potentially offering insights into combination strategies for AML management in Asian populations. The trial's continuation through 2025 indicates sustained scientific interest in optimizing cytarabine-based regimens. Success could support label expansions or new combination indications for cytarabine, though the program remains early-stage and results have not yet been disclosed. The competitive landscape includes established agents like EVOLTRA (clofarabine), which shares similar DNA polymerase inhibition mechanisms, and proteasome inhibitors such as KYPROLIS, reflecting the diversity of AML treatment approaches.

Drug Class: Antineoplastic and immunomodulating agents (ATC L01)

Modality: Small molecule

Primary Agent – Cytarabine:

• Mechanism of Action: DNA polymerase (alpha/delta/epsilon) inhibitor
• Target: DNA
• Route of Administration: Injection
• First Approval: Approved in the United States (NDA016793, NDA021041, NDA209401); approved in Australia (Pfizer, PBS codes 4357H, 7227J, first listed 1 December 2011); withdrawn from European Union (Pacira Limited, EMEA/H/C/000317, authorised 26 June 2017)
• Current US Sponsors: Multiple generic manufacturers including Fresenius Kabi USA, Gland, Hikma, Hospira, Jazz Pharmaceuticals Therapeutics, Meitheal, Pacira Pharmaceuticals, Pharmobedient, Quad Pharmaceuticals, Rising, Teva Parenteral, Teva Pharmaceuticals USA, and West-Ward Pharmaceuticals International

Secondary Agent – Chidamide:

• Mechanism of Action: Not yet disclosed
• Target: Not yet disclosed
• Route of Administration: Not yet disclosed
• Regulatory Status: Under clinical investigation in China; multiple ongoing trials (NCT02902185, NCT03031262, NCT03321890, NCT03974243, NCT05770882, NCT06386302, NCT06685276, NCT07397832)

United States: Cytarabine approved via multiple New Drug Applications (NDA016793, NDA021041, NDA209401) and Abbreviated New Drug Applications (ANDA071248, ANDA071249, ANDA071471, ANDA071472, ANDA071868, ANDA072168, ANDA072945, ANDA074245, ANDA075206, ANDA075383, ANDA076512, ANDA200914, ANDA200915, ANDA200916, ANDA201784, ANDA205696, ANDA206189, ANDA206190, ANDA208485, ANDA211937, ANDA211938) across multiple manufacturers.

Australia: Cytarabine approved and listed on the Pharmaceutical Benefits Scheme (PBS codes 4357H, 7227J) via Pfizer Australia Pty Ltd; first listed 1 December 2011.

European Union: Cytarabine (DEPOCYTE) authorised 26 June 2017 under EMEA/H/C/000317 (Pacira Limited) but subsequently withdrawn from the market.

China: Cytarabine and chidamide both under clinical investigation; multiple ongoing trials registered (NCT03031262, NCT03356080, NCT04121819, NCT07301138 for cytarabine; NCT02902185, NCT03031262, NCT03321890, NCT03974243, NCT05770882, NCT06386302, NCT06685276, NCT07397832 for chidamide).

Investigator-Initiated Trial: Regulatory pathway and approval strategy for the combination regimen not yet disclosed. Sponsor is Hospital Authority, Hong Kong; no commercial partner identified.

Strategic Implications: This investigator-initiated trial represents a non-traditional development pathway, with Hospital Authority, Hong Kong serving as sponsor rather than a pharmaceutical company. Such academic-led trials often generate real-world evidence and may inform future commercial development strategies, though they typically lack dedicated regulatory infrastructure and commercialisation resources. The combination of cytarabine (a mature, generic agent) with chidamide (an investigational compound in China) suggests a focus on optimising existing therapies rather than pursuing novel molecular entities.

Competitive Positioning: Cytarabine's generic status and widespread availability limit commercial upside for the combination approach unless chidamide demonstrates compelling clinical benefit. The trial's continuation through May 2025 indicates sustained scientific interest, but absence of disclosed results or next milestones suggests either slow recruitment, extended follow-up periods, or delayed reporting. Competitors with novel mechanisms (proteasome inhibitors, tyrosine kinase inhibitors) may offer differentiated clinical profiles if efficacy and safety data favour combination approaches.

Future Catalysts: Key catalysts include: (1) publication of Phase 2 efficacy and safety data; (2) regulatory feedback from Chinese authorities regarding chidamide's development status; (3) potential expansion to Phase 3 if Phase 2 endpoints are met; (4) comparative efficacy data versus established AML regimens. Absence of disclosed next milestones or expected completion dates limits visibility into trial progress.

Commercial Considerations: Limited commercial opportunity exists for cytarabine itself, given generic competition and mature market status. Value creation would depend entirely on chidamide's regulatory approval pathway in China and potential label expansion claims. No licensing or partnership arrangements are documented, suggesting this remains a purely academic research initiative without pharmaceutical industry involvement.